Results 71 to 80 of about 64,256 (179)

Systemic Mastocytosis [PDF]

, 2020
Kristen Gonter-Aubin, Andrew Kuykendall
  +5 more sources

Multifocal colonic mastocytosis mimicking ischaemic colitis: a rare cause of lower gastrointestinal bleeding

European Journal of Case Reports in Internal Medicine
Introduction: Mastocytosis is a rare clonal disorder characterised by abnormal proliferation and accumulation of mast cells in one or more organs. Although gastrointestinal symptoms are common in systemic mastocytosis, direct mucosal infiltration by ...
Karam Karam, Kim Charro, Aurélien Morini, Emilien Brousset, Christophe Locher   +4 more
doaj   +1 more source

Challenges in the Diagnosis of Cutaneous Mastocytosis

Diagnostics
Background: Mastocytosis is characterized by an accumulation of clonal mast cells (MCs) in tissues such as the skin. Skin lesions in mastocytosis may be clinically subtle or heterogeneous, and giving the correct diagnosis can be difficult.
Knut Brockow, Rebekka Karolin Bent, Simon Schneider, Sophie Spies, Katja Kranen, Benedikt Hindelang, Zsuzsanna Kurgyis, Sigurd Broesby-Olsen, Tilo Biedermann, Clive E. Grattan   +9 more
doaj   +1 more source

Bullous mastocytosis

Indian Journal of Dermatology, 2007
Mastocytosis is a condition characterized by the disorderly infiltration of mast cells in several tissues and comprises many different clinical situations varying from indolent cutaneous forms to malignant and systemic conditions. Bullous mastocytosis is
Nayak Surajit, Acharjya Basanti, Devi Basanti, Behera Samira   +3 more
doaj  

Novel approaches to treating advanced systemic mastocytosis

Clinical Pharmacology: Advances and Applications, 2019
JA Gilreath,1 L Tchertanov,2 MW Deininger31Department of Pharmacotherapy, College of Pharmacy and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA; 2Centre de Mathématiques et de Leurs Applications (CMLA-CNRS), ENS ...
Gilreath JA, Tchertanov L, Deininger MW
doaj  

Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosis. [PDF]

World Allergy Organ J
Pongdee T, Castells M, Akin C, Dybedal I, Gotlib J, Panse JP, Alvarez-Twose I, Cabeza CM, Cerquozzi S, Vadas P, Swarup V, Vachhani P, Wortmann F, Yi CA, Bidollari I, Newberry K, Shaheen D, Hartmann K.   +17 more
europepmc   +1 more source

Advances in the Management of Mediator-Related Symptoms in Non-Advanced Systemic Mastocytosis. [PDF]

Immunotargets Ther
Gülen T, Sabato V.
europepmc   +1 more source

Nemolizumab as an Alternative Therapeutic Option for Indolent Systemic Mastocytosis. [PDF]

Cureus
Minbaeva S, Tyring SK.
europepmc   +1 more source

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study. [PDF]

Blood Adv
Gotlib J, Reiter A, Radia DH, Álvarez-Twose I, Deininger MW, George TI, Panse J, Mital A, Pettit KM, Vannucchi AM, Platzbecker U, Hermine O, Elshoury A, Livideanu CB, Mesa R, Ustun C, Triggiani M, Dybedal I, Jurcic JG, Zanotti R, Oh ST, Yacoub A, Hexner EO, Bose P, Lee SG, Sperr WR, Griffiths EA, Butler M, Lübke J, Bidollari I, Lin HM, Rylova S, Dimitrijević S, Muñoz-González JI, DeAngelo DJ.   +34 more
europepmc   +1 more source

Psychometric evaluation of the Mastocytosis Symptom Severity Daily Diary (MS2D2) in adults with nonadvanced systemic mastocytosis (NonAdvSM). [PDF]

Qual Life Res
Marcus JC, Akin C, Zhang J, Easton R, Lim-Watson M, Siebenhaar F, Gwaltney C, Turner R.   +7 more
europepmc   +1 more source